Wave Q2 Results, dosing in obesity trial
Wave reported Q2 financial results with $490.6M in cash as of June 30, 2026, noting dosing underway in its Phase 2a obesity trial and data supporting a potential accelerated approval for WVE-006.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day